At the beginning of 2018, PuriPharm Co., Ltd. and Huzhou Center of Industrial Biotechnology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (CAS), signed the cooperation agreement on seeking common development by jointly establishing the Puri Joint Research and Development Laboratory.
Puripharm Co., Ltd. is a company specializing in the development, production and application of functional bioactive ingredients and preparations. Currently the company has developed a series of bioactive ingredients by chemical synthesis, plant extraction and biotechnology, as well as new pharmaceutical and bioactive ingredients preparations based on nano-delivery system, etc.
The Huzhou Center of Industrial Biotechnology, Shanghai Institutes for Biological Sciences, CAS, was formally established in October, 2006, which is a technological platform that integrates industrialization research and development (R&D) with technological transfer, jointly built by the Huzhou Municipal People’s Government and Shanghai Institutes for Biological Sciences, CAS. Since its establishment, there has been more than 20 industrialization projects, and the cooperative enterprises have realized the project output value of more than 800 million yuan. Based in Huzhou, neighboring Shanghai and expanding to the Yangtze River Delta, the center owns an excellent technical R&D team in genetic engineering, enzyme engineering, separation and purification, pilot research and analysis, mainly focusing on industrial biotechnology (R&D, transformation on achievements and industrialized implementation) according to the characteristics of regional industries with the aim of promoting the structural adjustment and industrialization level of bio-industry in Huzhou and surrounding areas thereby boosting local and regional economic development.
In-depth R&D cooperation will be carried out on biomedical products that are of mutual concerns based on the complementary technological advantages of the two sides, with the expectations to achieve industrialization within three years.
The article has been revised in 2018-07-13